From overcoming to exploiting hypoxia: a metronidazole-armed type I photosensitizer for septic arthritis therapy.

Authors

Meng-Die Wang, Kun-Mei Liu, Jin-Yu An, Yuan Chen, Shun Feng, Ming-Yu Wu

Published in

Journal of materials chemistry. B. Oct 12, 2026. Epub Oct 12, 2026.

Abstract

Septic arthritis is a life-threatening joint infection with high mortality, yet clinical antibiotic and surgical treatments usually cause increasing drug resistance and irreversible tissue damage. Photodynamic therapy (PDT) offers a non-invasive alternative with low drug resistance. However, its efficacy in septic arthritis is severely hampered by the intra-articular hypoxia. To address this issue, we propose an innovative strategy that shifts from overcoming hypoxia to fully exploit hypoxia. Accordingly, we developed a metronidazole-functionalized Type I cationic photosensitizer (PS), ACR-DM-MNZ. It anchors onto bacterial surfaces via electrostatic interactions and, importantly, leverages hypoxia-overexpressed nitroreductase to reduce its nitro group, thereby enhancing bacterial membrane binding and toxicity. Upon white light irradiation, it generates hydroxyl radicals (˙OH) to kill bacteria and eliminate biofilms. In a murine model of MRSA-induced septic arthritis, under light irradiation, ACR-DM-MNZ effectively eradicated intra-articular pathogens, alleviated joint swelling, modulated inflammation, reduced histopathological damage, and promoted joint repair. This work presents an efficient strategy that transforms the hypoxic barrier into a therapeutic asset, offering a promising platform for the treatment of septic arthritis.

PMID:
42862162
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.